These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26951451)

  • 21. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
    McCarty D; Robinson A
    Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels.
    Sabor L; Raphaël M; Dogné JM; Mullier F; Douxfils J
    Thromb Res; 2017 Aug; 156():36-38. PubMed ID: 28582639
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral Anticoagulants: The Move Beyond Warfarin.
    Carroll VS; Frei J
    J Neurosci Nurs; 2016; 48(4):177. PubMed ID: 27254485
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19.
    Bosch FTM; Candeloro M; Potere N; Porreca E; Di Nisio M; Kamphuisen PW
    Thromb Res; 2021 Sep; 205():106-109. PubMed ID: 34293538
    [No Abstract]   [Full Text] [Related]  

  • 25. A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
    Thalji NK; Ivanciu L; Davidson R; Gimotty PA; Krishnaswamy S; Camire RM
    Nat Med; 2016 Aug; 22(8):924-32. PubMed ID: 27455511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urgent Need to Measure Effects of Direct Oral Anticoagulants.
    Weitz JI; Eikelboom JW
    Circulation; 2016 Jul; 134(3):186-8. PubMed ID: 27436877
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comment on: Andexanet alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.].
    Lier H; Grottke O
    Anaesthesist; 2016 Dec; 65(12):940-942. PubMed ID: 27778054
    [No Abstract]   [Full Text] [Related]  

  • 28. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
    Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
    Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
    Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Andexanet Alfa: First Global Approval.
    Heo YA
    Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
    Verhoef D; Visscher KM; Vosmeer CR; Cheung KL; Reitsma PH; Geerke DP; Bos MHA
    Nat Commun; 2017 Sep; 8(1):528. PubMed ID: 28904343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment with NAO in acute coronary syndromes: rationale and clinical data.
    Lettino M
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1():e129-e133. PubMed ID: 28240991
    [No Abstract]   [Full Text] [Related]  

  • 33. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
    Bhatt MD; Paes BA; Chan AK
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
    Vanassche T; Vandenbriele C; Peerlinck K; Verhamme P
    Expert Opin Pharmacother; 2015 Apr; 16(5):645-58. PubMed ID: 25554350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of bleeding in patients receiving non-vitamin K antagonists.
    Balla S; Koerber S; Flaker G
    Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Betrixaban - the next direct factor Xa inhibitor?
    Thoenes M; Minguet J; Bramlage K; Bramlage P; Ferrero C
    Expert Rev Hematol; 2016 Dec; 9(12):1111-1117. PubMed ID: 27809616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Xa activity in VTE patients treated with fondaparinux.
    Ota S; Wada H; Mastuda A; Ogihara Y; Yamada N; Nakamura M; Ito M
    Clin Chim Acta; 2015 Mar; 442():22-3. PubMed ID: 25584459
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of the oral direct factor Xa inhibitor - betrixaban.
    Palladino M; Merli G; Thomson L
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1465-72. PubMed ID: 23964817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.